Clinical Evidence: What STEP Trials Reveal About Costs vs Results
Is Wegovy Cheaper Than Mounjaro: Understanding UK Weight Loss Trial Evidence
When evaluating whether Wegovy is cheaper than Mounjaro, UK patients must consider clinical evidence alongside pricing structures. Wegovy benefits from extensive STEP trial data spanning multiple years, demonstrating consistent weight management outcomes in diverse patient populations. The STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine (2021), showed patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo.
Mounjaro, containing tirzepatide as a dual GIP and GLP-1 receptor agonist, represents newer technology with promising early results, though long-term data remains limited compared to Wegovy's established evidence base. Both prescription-only medicines require clinical assessment and ongoing medical supervision, making the cost comparison more complex than simple price-per-pen calculations. Your prescriber can evaluate which treatment offers better value based on your individual medical history, weight management goals, and response to therapy.
Wegovy vs Mounjaro Pricing: Complete UK Cost Breakdown
At EverydayMeds, Wegovy pricing starts at £79.99 for the 0.25mg starter dose, escalating through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our bundle options provide supply convenience, with the Intro Duo (0.25mg and 0.5mg) priced at £169.99, covering your first eight weeks of treatment. New customers benefit from discount code FIRST40, while returning patients use DOSE25 at checkout, with these reductions already reflected in our published prices.
Mounjaro follows a different dose escalation schedule with distinct pricing, though both treatments require similar clinical oversight and cold-chain delivery logistics. When comparing whether Wegovy is cheaper than Mounjaro over a complete treatment cycle, consider that maintenance doses represent your primary long-term investment. Both medications are available through our GPhC-registered pharmacy (#9012878) with identical clinical assessment requirements and next-day delivery service standards.
STEP Trial Results: Wegovy's Evidence-Based Weight Loss Performance
The comprehensive STEP clinical trial programme provides robust evidence for Wegovy's effectiveness in UK weight management contexts. STEP 3 demonstrated approximately 16% average weight loss when Wegovy was combined with intensive behavioural therapy, while STEP 5 confirmed sustained weight loss of 15.2% maintained over two years. These results represent outcomes achieved by participants following prescribed protocols alongside reduced-calorie diets and increased physical activity.
Most significantly for UK patients concerned about cardiovascular health, the SELECT trial revealed a 20% reduction in major cardiovascular events among participants taking Wegovy. This evidence extends beyond simple weight management, suggesting broader health benefits that may justify cost considerations when determining whether Wegovy is cheaper than Mounjaro in terms of overall health value.
How Wegovy Works: GLP-1 Mechanism for Appetite Control
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormones to reduce appetite and promote satiety after smaller meals. This mechanism works on brain appetite centres, potentially reducing food cravings and helping you feel satisfied with appropriate portion sizes. Unlike surgical interventions, Wegovy offers a reversible approach to weight management that can be discontinued if circumstances change. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system provides convenience compared to daily medications. However, Wegovy must be used alongside lifestyle modifications including reduced-calorie diets and increased physical activity to achieve optimal results, making it part of a comprehensive weight management strategy rather than a standalone solution.
EverydayMeds Ordering: From Assessment to Delivery
Our streamlined process begins with a 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. UK-qualified prescribers review your application within 3 working days (or 24 hours with express service) to ensure Wegovy or Mounjaro suits your individual circumstances. Once approved, we dispatch your prescription-only medicine via next-day delivery using specialized cold-chain packaging to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) handles all regulatory compliance, ensuring you receive genuine medication with full traceability and safety documentation. This comprehensive service addresses the question of whether Wegovy is cheaper than Mounjaro by providing identical clinical standards regardless of your chosen treatment.
Storage and Practical Considerations: Wegovy vs Mounjaro Convenience
Wegovy offers superior storage flexibility, remaining stable for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This advantage proves particularly valuable for UK patients who travel frequently or face unpredictable schedules. Both medications require refrigeration at 2-8°C before first use and utilize similar injection pen technology. The dose escalation schedule for Wegovy spans 16 weeks from 0.25mg starter dose to 2.4mg maintenance, allowing your body to adapt gradually while minimizing side effects. You cannot skip doses or accelerate the escalation timeline, making treatment predictability an important factor when comparing long-term costs and planning your medication budget.
Cost-Effectiveness Analysis: Long-Term Value Beyond Initial Pricing
Determining whether Wegovy is cheaper than Mounjaro requires evaluation beyond initial prescription costs to include long-term health outcomes and treatment sustainability. Wegovy's extensive STEP trial evidence provides greater confidence in predicting long-term results, potentially reducing the risk of treatment switches or additional interventions. The medication's proven cardiovascular benefits may translate into reduced healthcare costs for patients with existing heart disease risk factors.
However, individual response varies significantly, and some patients may achieve better results with Mounjaro's dual-hormone approach despite higher initial costs. Both treatments represent substantial investments in your health, with maintenance doses continuing indefinitely for sustained weight management. STEP 1 extension data shows patients typically regain approximately two-thirds of lost weight within one year of discontinuing treatment, emphasizing that successful weight management requires long-term commitment regardless of which medication you choose.
Making Your Decision: Expert Guidance for Treatment Selection
Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to recommend the most appropriate option based on your medical profile rather than cost constraints alone. Our clinical team considers factors including your previous weight loss attempts, medical conditions, medication interactions, and lifestyle preferences when guiding treatment selection. NICE guidelines (TA875) recommend Wegovy with specialist weight management support, providing additional NHS context for treatment decisions.
Rather than focusing solely on whether Wegovy is cheaper than Mounjaro, we encourage UK patients to prioritize clinical suitability and evidence-based outcomes. Our competitive pricing structure ensures both treatments remain accessible, while our discount codes (FIRST40 for new customers, DOSE25 for returning patients) help manage initial costs. Your investment in either treatment should align with realistic expectations and commitment to accompanying lifestyle modifications for optimal results.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
